The positive efficacy results obtained with HDAC inhibitors as anticancer agents resulted in the approval of HDAC inhibitors by the US Food and Drug Administration (USFDA) for the treatment of some cancer subtypes [20,21]. Here, HDAC9 is linked to cancer.